Premium
Potential of Nociceptin/Orphanin FQ Peptide Analogs for Drug Development
Author(s) -
Wtorek Karol,
Janecka Anna
Publication year - 2021
Publication title -
chemistry and biodiversity
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.427
H-Index - 70
eISSN - 1612-1880
pISSN - 1612-1872
DOI - 10.1002/cbdv.202000871
Subject(s) - nociceptin receptor , nop , chemistry , receptor , opioid peptide , opioid , peptide , pharmacology , opioid receptor , biochemistry , biology
Nociceptin receptor (NOP) belongs to the family of opioid receptors but was discovered and characterized much later than the so called classical opioid receptors, μ, δ and κ (or MOP, DOP and KOP, resp.). Nociceptin/orphanin FQ (N/OFQ) is the endogenous ligand of this receptor and it controls numerous important functions in the central nervous system and in the periphery, so its analogs may be developed as innovative drugs for the treatment of a variety of conditions and pathological states. Availability of potent and selective ligands with high affinity to NOP receptor is essential to fully understand the role of NOP‐N/OFQ system in the body, which in turn may lead to designing novel therapeutics. Here, we have focused on reviewing the structure of potent peptide‐based agonists, antagonists, biased analogs and bivalent ligands that target NOP receptor.